Democritus University of Thrace (DUTH)
Πρότυπα λειτουργίας ανοσολογικού συστήματος μετά από μεταμόσχευση αλλογενών αιμοποιητικών κυττάρων
Abstract
dc:descriptionImmune reconstitution post allogeneic hematopoetic transplantation (allo-HCT) occurs sequentially for different cell populations and depends on factors that are patient-related (age, disease), graft- or complication- related (Graft Versus Host Disease, GvHD, infections). Delayed immune reconstitution involves a delay in the recovery of a broad, representative T lymphocyte repertoire, active against several immune pathogens. Immunodeficiency leads to major complications, such as infections, relapse and secondary malignancies. Post transplantation expansions of T cytotoxic lymphocytes have been widely discussed in the literature. They represent a wide spectrum of lymphoproliferations, ranging from polyclonal transient expansions to persisting monoclonal malignancies of T Large granular lymphocytes, LGLs. It is implied that in immunocompromized patients a chronic antigenic stimuli (malignancy or virus) can disrupt immune-surveillance and give rise to excessive lymphoproliferations. Similar T-LGL expansions have been described from our group in patients with malignancy after Rituximab administration. In order to elucidate the dynamic evolution of a transient polyclonal lymphoproliferation into a clonal population we studied the immune reconstitution of allo- transplanted patients post Rituximab administration, by extensive immunoprofilling of the variable region of β chain of T cell receptor (TR). Fourteen patients who underwent allo-HCT from a sibling or matched volunteer donor and received Rituximab were included in the study. Bone marrow samples were analyzed at a median of 5 months (range 1-23) post Rituximab and 18 months (range 4-64) post allo-HCT. In two patients samples pre- and post Rituximab were studied. In patients with lymphocytosis or unexplained neutropenia lymphocyte subpopulations were studied with flow cytometry in parallel. Immunoprofiling of TR consisted of PCR amplification of the variable region of β chain, cloning and Sanger sequencing. Immunogenetic analysis was performed using imgt tools. In total, flow cytometry revealed a low ratio of CD4/CD8 and complete absence of B-cells. Most of the patients presented with increased number of CD8+ cells (>1.0 x 109/L in 6/9 patients) and increased (>30%) percentage of CD3+CD8+CD57+ Τ-LGLs (>30% in 7/9 patients). Molecular profiling consisted of 288 productive TRBV-TRBD-TRBJ gene rearrangements in 17 samples (6–91/ sample, median: 14). Longitudinal samples were analyzed in two patients. A remarkable skewing in the use of TRBV genes was observed, with 3 TRBV genes accounting for almost half of the total repertoire of TRBV-TRBD-TRBJ gene rearrangements(TRBV6-5*01: 32%, TRBV27*01: 11.4% και TRBV19-01: 7.6%). Expanded clonotypes (>=2 similar rearrangements) were detected in all patients. In 7/14 patients more than half of the TR gene repertoire consisted of 2-3 expanded clonotypes. To study clinicobiological correlations, we restricted the analysis to 9 patients in whom at least 10 productive rearrangements were available. Oligoclonality was even more pronounced: in seven of 9 patients Τ repertoires, consisted of expanded clonotypes at a median of 89% of all identified rearrangements (range 66-100%). Viral reactivation could be related to oligoclonality: all patients with oligoclonality but none with a polyclonal background experienced EBV reactivation and 4/7 oligoclonal vs 1/2 polyclonal experienced CMV reactivation. Six of 7 patients with oligoclonal versus 1/2 patients with polyclonal repertoire presented chronic GvHD. One patient with a remarkably oligoclonal repertoire at +3 and +12 months eventually developed T-LGL leukemia of donor origin 8 years post allo-HCT by expansion of TRBV2*01/TRBD1*01/TRBJ1-5*01 clonotype. Distinct clonotypes predominated at different time-points, suggesting clonal drift. The patient had a symptomatic T-LGL leukemia of donor origin along with a low donor chimerism in the bone marrow, without ever experiencing a relapse from the underlying Ph+ ALL. In conclusion, we report the frequent development of oligoclonal cytotoxic T-cell populations after Rituximab treatment post allo-HCT, likely of multifactorial origin. The observed association of oligoclonality with GvHD and the development of a possible “T-LGL leukemia vs leukemia” effect in one patient implies an anti-leukemic effect of this phenomenon. Finally, the observed skewing of the TR gene repertoire strongly implicates antigen selection in the development of cytotoxic T-LGL expansions after allo-HCT.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papalexandri, Apostolia
- Παπαλεξανδρή, Αποστολία
Subjects
dc:subject × 9Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/46103